This is a multi-center, single arm open label phase 1b/2 study of pembrolizumab in combination with 177Lu-PNT2002 (also known as 177Lu-PSMA I&T) radiopharmaceutical therapy in patients with metastatic clear cell renal cell carcinoma (RCC) who have progressed after prior treatment with anti-programmed cell death protein 1 (PD1) or PD-L1 immune-checkpoint inhibitors (ICIs). The study comprises 2 phases: an open-label Phase 1b dose escalation portion followed by a Phase 2 dose expansion portion. Investigators hypothesize that pembrolizumab in combination with 177Lu-PNT2002 in in patients with metastatic clear cell RCC at a biologically active dose will result in tolerable safety profile and it will lead to improved radiological objective responses in patients who have progressed after prior treatment with standard anti-PD1 or anti- Programmed Cell Death Ligand 1 (PDL1) immune-checkpoint inhibitor containing regimen when compared to historic controls. Patients in both phases will have prostate-specific membrane antigen (PSMA), positron emission tomography (PET) imaging with the radiotracer (F-18)-DCFPyl, to help detect any spread of the cancer.

Start Date01 Jul 2024

Sponsor / Collaborator

The Sidney Kimmel Comprehensive Cancer Center

[+2]

NCT05896371 / Not yet recruitingPhase 1/2

PROstate-specific Membrane Antigen DosImetry-Guided endoradiotherapY: A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy (PRODIGY-1)

The goal of this clinical trial is to study a personalized regime of lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) in patients with progressive and/or symptomatic, inoperable PSMA-expressing cancers of prostatic or other origins.
The main questions it aims to answer are:
To establish a dosimetry-based, personalized regime of 177Lu-PSMA
To report on the efficacy of personalized 177Lu-PSMA
Participants (stratified by risk factors of toxicity) will receive up to 6 cycles of a personalized activity of 177Lu-PSMA based on renal dosimetry. In the phase 1, the prescribed absorbed dose to the kidney will be escalated, to determine the regime that will be administered in the phase 2. The best response within 12 months after the first cycle will be assessed. Salvage treatment of 3 cycles may be offered to responders after re-progression.

Start Date29 Jan 2024

Sponsor / Collaborator

Centre Hospitalier Universitaire (CHU) de Québec-Université Laval

[+1]

IRCT20230803059015N1 / SuspendedPhase 2IIT

Evaluating the theranostic application of Lu177-PSMA in management of refractory thyroid papillary cancer.

Start Date23 Aug 2023

Sponsor / Collaborator

Shiraz University of Medical Sciences

100 Clinical Results associated with 177Lu-PSMA-I&T

100 Translational Medicine associated with 177Lu-PSMA-I&T

100 Patents (Medical) associated with 177Lu-PSMA-I&T

Literatures (Medical) associated with 177Lu-PSMA-I&T

01 Jan 2024·Asia Oceania journal of nuclear medicine & biology

Formulating a national position statement and guide on modern theranostics in the Philippines.

Article

Author: Bautista-Peñalosa, Patricia A ; San Luis, Teofilo O L ; Barrenechea, Emerita A ; M Estrada, Francis Gerard

Barriers to the establishment of advanced technologies in developing countries were overcome when modern theranostics pertaining to the use of Ga-68 and Lu-177 PSMA and DOTATATE were first offered to patients in the Philippines in early 2018. However, significant growth was not experienced at St. Luke's Medical Center for five years and lutetium was not yet distributed to other institutions by a radiopharmaceutical supplier. Due to the relative novelty and rapid expansion of theranostics worldwide, position statements were released by the Australasian Association of Nuclear Medicine Specialists, European Association of Nuclear Medicine, Society of Nuclear Medicine and Molecular Imaging, and International Atomic Energy Agency primarily to uphold patient safety and ensure a level of standard among its practitioners. Subsequently in the latter half of 2022, these were adopted and modified according to what is feasible and applicable locally within the Philippine Society of Nuclear Medicine, considering the current status and future possibilities. Different representatives were involved, and several groups were mobilized for successful implementation. A liability clause was incorporated to discourage unprofessional acts.

31 Dec 2023·Journal of medical economics

Costs of radium-223 and the pharmacy preparation ¹⁷⁷ Lu-PSMA-I&T for metastatic castration-resistant prostate cancer in Dutch hospitals

Article

Author: Wyndaele, D. N. J. ; Quist, S. W. ; Paulissen, J. H. J. ; Nagarajah, J. ; Freriks, R. D.

OBJECTIVE:

The radiopharmaceuticals radium-223 and the pharmacy preparation ¹⁷⁷Lu-PSMA-I&T are reimbursed in the Netherlands for metastatic castration-resistant prostate cancer (mCRPC) treatment. Although shown to be life-prolonging in patients with mCRPC, the treatment procedures associated with these radiopharmaceuticals can be challenging for both patients and hospitals. This study investigates the costs of mCRPC treatment in Dutch hospitals for currently reimbursed radiopharmaceuticals with a demonstrated overall survival benefit.

METHODS:

A cost model that calculated the direct medical per-patient costs of radium-223 and ¹⁷⁷Lu-PSMA-I&T was developed, following clinical trial regimens. The model considered six 4-weekly administrations (i.e. ALSYMPCA regimen) of radium-223. Regarding ¹⁷⁷Lu-PSMA-I&T, the model used both the VISION regimen (i.e. five 6-weekly administrations) and the SPLASH regimen (i.e. four 8-weekly administrations). Based on health insurance claims, we also estimated the coverage a hospital would receive for providing treatment. No fitting health insurance claim for ¹⁷⁷Lu-PSMA-I&T is currently available; therefore, we calculated a break-even value for a potential health insurance claim that would exactly counterbalance the per-patient costs and coverage.

RESULTS:

Radium-223 administration is associated with per-patient costs of €30,905, and these costs are fully covered by the coverage a hospital receives. The per-patient costs of ¹⁷⁷Lu-PSMA-I&T range between €35,866 and €47,546 per administration period, depending on the regimen. Current healthcare insurance claims do not fully cover the costs of providing ¹⁷⁷Lu-PSMA-I&T: hospitals must pay €4,414-€4,922 for each patient out of their own budget. The break-even value for the potential insurance claim covering ¹⁷⁷Lu-PSMA-I&T administration with a VISION (SPLASH) regimen is €1,073 (€1,215).

CONCLUSION:

This study shows that, without consideration of the treatment effect, radium-223 treatment for mCRPC leads to lower per-patient costs than treatment with ¹⁷⁷Lu-PSMA-I&T. The detailed overview of the costs associated with radiopharmaceutical treatment provided by this study is relevant for both hospitals and healthcare insurers.

01 Dec 2023·Clinical nuclear medicine

Radioligand Therapy With 177Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer

Article

Author: Esen, Tarık ; Mandel, Nil Molinas ; Esen, Barış ; Falay, Okan ; Demirkol, Mehmet Onur ; Seymen, Hülya ; Tilki, Derya ; Kurtuldu, Sevgilay ; Uçar, Burcu ; Şen, Melis ; Bavbek, Sevil

Introduction:

This study aimed to investigate the oncological outcomes and toxicity profile of 177Lu-PSMA-I&T radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC), as well as our initial experience in metastatic hormone-sensitive prostate cancer (mHSPC).

Patients and Methods:

A total of 38 consecutive patients with metastatic prostate cancer (33 mCRPC and 5 mHSPC) received 177Lu-PSMA-I&T RLT, with a median of 2 cycles per patient (range, 1–7). Response to RLT was evaluated based on prostate-specific antigen (PSA) changes and imaging response. Clinical progression-free survival and overall survival were used to report oncological outcomes. Toxicity was assessed using the Common Toxicity Criteria for Adverse Events criteria.

Results:

In mCRPC, 22 (69%), 18 (56%), and 11 (34%) patients achieved any PSA decline, PSA response of ≥30%, and PSA response of ≥50%, respectively. The clinical progression-free survival and overall survival after the first cycle of RLT were 6.3 and 21.4 months, respectively. In mHSPC, 177Lu-PSMA-I&T RLT resulted in excellent PSA response (93.0%–99.9%) in all cases. Clinical progression and cancer-related mortality occurred in only 1 case. Toxicity profile was favorable in both mHSPC and mCRPC.

Conclusions:

177Lu-PSMA-I&T RLT demonstrated favorable PSA response (≥30%) in over half of the patients with mCRPC and excellent PSA response in all patients with mHSPC. Toxicity profile was favorable in both mHSPC and mCRPC settings. Further studies are needed to evaluate the role of 177Lu-PSMA-I&T RLT in the management of metastatic prostate cancer.

News (Medical) associated with 177Lu-PSMA-I&T

11 Sep 2023

·www.biospace.com

Blue Earth Therapeutics Announces Promising Results of Preclinical Evaluation of 225Ac-rhPSMA-10.1 for Potential Targeted Alpha Therapy of Prostate Cancer

− 225Actinium-labeled radiohybrid Prostate-Specific Membrane Antigen (225Ac-rhPSMA-10.1) is in development as a highly optimized, next generation therapeutic radiopharmaceutical – − 225Ac-rhPSMA-10.1 demonstrated favorable, significant tumor growth reduction in preclinical models – − Abstract recognized as Top Rated Oral Presentation by European Association of Nuclear Medicine − − Planned studies using 225Ac radioisotope complement Company’s ongoing Phase 1/2 clinical trial of 177Lu-rhPSMA-10.1 in men with metastatic castrate resistant prostate cancer – This press release is for U.S. audiences only MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)-- Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced results from a series of preclinical analyses designed to evaluate the binding affinity, lipophilicity, cellular internalization and therapeutic efficacy of 225Ac-rhPSMA-10.1 in preclinical models for the treatment of prostate cancer, using 177Lu-rhPSMA-10.1 as a comparator. Results showed that both 225Ac-rhPSMA-10.1 and 177Lu-rhPSMA-10.1 demonstrated excellent PSMA binding affinity, high cellular internalization and similar lipophilicity. Therapeutic response and efficacy were evaluated in a preclinical prostate cancer model which showed that 225Ac-rhPSMA-10.1 significantly suppressed tumor growth relative to control. The data were presented in an oral presentation at the Annual Congress of the European Association of Nuclear Medicine (EANM’23) in Vienna, Austria. 225Ac-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, and the lead alpha-emitting candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. “We are pleased that the first presentation of preclinical results from Blue Earth Therapeutics’ prostate cancer program using rhPSMA-10.1 radiolabeled with 225Ac is being made to the nuclear medicine community at the EANM’23 Annual Meeting,” said David E. Gauden, D.Phil., Chief Executive Officer of the Company. “Underscoring our commitment to advancing science, we are also honored that the abstract has been recognized as a “Top Rated Oral Presentation” by the Association. 225Ac-rhPSMA-10.1 is our second pipeline compound, and, like our lead Phase 1/2 compound 177Lu-rhPSMA-10.1, it is based on innovative radiohybrid PSMA theranostic technology. The radiohybrid platform enables molecules within the class to be modified and deployed for either diagnostic PET imaging or therapeutic applications, and they can also be developed with both beta- and alpha-emitting therapeutic radioisotopes. The pharmacokinetic pro rhPSMA-10.1 was carefully optimized during development to deliver high radiation doses to prostate cancer lesions while sparing normal tissues as far as possible, and we are building on that work by radiolabeling it with the powerful alpha-emitting radioisotope, 225Ac. Dr. Gauden continued, “Results from these preclinical analyses demonstrate a promising therapeutic pro 225Ac-rhPSMA‑10.1, while using 1,000-fold lower radioactivity than 177Lu-rhPSMA-10.1, with similar in vitro characteristics and in vivo therapeutic efficacy observed for both compounds. 225Ac-rhPSMA-10.1 represents a novel alpha-targeted therapy that we intend to advance into the clinic. IND-enabling studies have been completed and we plan to initiate a Phase 1 clinical study of 225Ac-rhPSMA-10.1 in the first half of 2024.” About the study The findings presented at EANM’23 evaluated 225Ac-rhPSMA-10.1 and 177Lu-rhPSMA-10.1 in preclinical models for the treatment of prostate cancer. Binding affinity and cellular internalization assays were conducted in LNCaP cells, using 177Lu-PSMA-I&T as a reference compound. The lipophilicity of 225Ac-rhPSMA-10.1 and 177Lu-rhPSMA-10.1 was determined by the shake-flask method, measuring the distribution coefficient in n-octanol and PBS at pH 7.4 (log D7.4). Therapeutic response to single-administration of 225Ac-rhPSMA-10.1 (30 kBq) or 177Lu-rhPSMA-10.1 (30 MBq) was evaluated in the 22Rv1 preclinical model (n=8 per group). Efficacy was assessed based on relative tumour growth (change in tumour volume from treatment administration day/baseline) and survival of treated groups versus untreated controls ≤49 days post-treatment initiation. Body weights were monitored throughout for toxicity assessment. Results Both natLa-rhPSMA-10.1 and natLu-rhPSMA-10.1 (natLa and natLu being cold surrogates of 225Ac and 177Lu) showed excellent PSMA binding affinity (IC50 = 3.6±0.6 nM and 1.6±0.1 nM, respectively). High cellular internalization and similar lipophilicity were observed for both 225Ac-rhPSMA‑10.1 and 177Lu-rhPSMA-10.1 (% internalization = 99±14 and 108±5; logD7.4 = -3.4±0.2 and -3.8±0.1; respectively). 225Ac-rhPSMA-10.1 treatment significantly reduced tumour growth in vivo versus controls (from day 14 to 31, p<0.05), and prolonged survival (median survival: 27, 43.5, and 42 days for untreated, 225Ac-rhPSMA-10.1, and 177Lu-rhPSMA-10.1 groups, respectively). There were no significant differences in tumour growth suppression or survival between the 225Ac‑rhPSMA-10.1 and 177Lu-rhPSMA-10.1 groups, and both treatments were well-tolerated. The results were discussed in an oral presentation, “Preclinical Evaluation of 225Ac-rhPSMA-10.1, a Novel Radiohybrid PSMA Compound for Targeted Alpha Therapy of Prostate Cancer,” by Caroline Foxton, Ph.D., Blue Earth Group, Oxford, UK, at the Annual Congress of the European Association of Nuclear Medicine on September 10, 2023. Full session details and the abstract are available in the EANM online program here . About Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) rhPSMA compounds are referred to as radiohybrid (“rh”), as each molecule possesses three distinct domains. The first consists of a Prostate-Specific Membrane Antigen-targeted receptor ligand which attaches to and is internalized by prostate cancer cells. It is attached to two labelling moieties which may be radiolabeled with diagnostic isotopes such as 18F or 68Ga for PET imaging, or with therapeutic isotopes such as 177Lu or 225Ac for radioligand therapy – enabling the potential for a true theranostic technology. They may play an important role in patient management in the future, and offer the potential for precision medicine for men with prostate cancer. Radiohybrid technology and rhPSMA originated from the Technical University of Munich, Germany. Blue Earth Diagnostics acquired exclusive, worldwide rights to rhPSMA diagnostic imaging technology from Scintomics GmbH in 2018, and therapeutic rights in 2020, and has sublicensed the therapeutic application to its sister company Blue Earth Therapeutics. Blue Earth Therapeutics and Blue Earth Diagnostics work closely on the development of 177Lu-rhPSMA-10.1. Currently, Blue Earth Therapeutics’ rhPSMA compounds have not received regulatory approval. About Blue Earth Therapeutics Blue Earth Therapeutics, one of the Bracco family of companies, is a clinical stage company dedicated to advancing next generation targeted radiotherapeutics to treat patients who have cancer. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start-up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases. Blue Earth Therapeutics has an emerging pipeline, initially focused on prostate cancer, and with plans to expand into additional disease areas in oncology. Blue Earth Therapeutics is an indirect subsidiary of Bracco Imaging S.p.A, and based in Oxford, UK. For more information, please visit: . About Bracco Imaging Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose-management software. In 2019 Bracco Imaging enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology vehicle to develop radiopharmaceutical therapies. Visit: .

Clinical ResultAcquisitionRadiation Therapy

14 Mar 2023

·www.globenewswire.com

Curium Confirms No Supply Challenges in North America and Europe for its Eclipse Phase 3 Clinical Trial

To date, an uninterrupted supply of 177Lu-PSMA-I&TRobust supply chains and global transportation infrastructure deliver supply securityCurium’s clinical trials play central role in innovations in cancer patient care PARIS, March 14, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, confirmed today that the company has no foreseeable supply challenges of 177Lu-PSMA-I&T for the company’s ECLIPSE Phase 3 clinical trial (NCT05204927) ongoing in the USA, France, Spain, and Italy. Since patient enrollment started in March 2022, the ECLIPSE Phase 3 trial has experienced reliable and uninterrupted supply of 177Lu-PSMA-I&T. ECLIPSE is a Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer. Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented: “We continue to make strong progress in conducting our ECLIPSE Phase 3 clinical trial in North America and in Europe. Reliability of clinical trial supply is extremely important for our patients and investigators, and we are pleased to confirm that our clinical trial supply with 177Lu-PSMA-I&T remains uninterrupted. Curium is committed to the ECLIPSE clinical trial as well as our other ongoing clinical trials in oncology to further our mission of redefining the experience of cancer through our trusted legacy in nuclear medicine.” For more information about the ECLIPSE trial: www.eclipseclinicaltrial.org To locate a clinical trial site or contact Curium’s clinical trial: ECLIPSE@curiumpharma.com About Curium Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com For more information:Ross BethellVP, Head of Global Communicationscommunications@curiumpharma.com

Phase 3

07 Mar 2023

·www.prnewswire.com

Vancouver Clinic Earns Therapeutic License to Administer New Drug to Treat Prostate Cancer

"We are thrilled to offer this novel treatment in Canada to help prolong lives" VANCOUVER, BC, March 7, 2023 /PRNewswire/ - INITIO Medical Group is the first private nuclear medicine facility in Canada to be awarded a therapeutic license to administer Lutetium-177-PSMA (prostate specific membrane antigen) for the treatment of advanced prostate cancer, specifically "metastatic castration resistant prostate cancer" also known as "mCRPC". Lu-177-PSMA, an example of a new kind of cancer treatment called "RLT" (radioligand therapy), is a game-changer for those suffering from the advanced form of the most common cancer in Canadian men, and their third-leading cause of death from cancer. What makes Lu-177-PSMA and the coming wave of RLT compounds such cutting-edge treatments is that they target and destroy cancer cells precisely, while minimizing exposure to healthy tissue, often with fewer side effects than chemotherapy, traditional radiation and other treatments. "This therapeutic license allows us to offer this ground-breaking treatment to patients who may not have had access to it otherwise," says Dr. Kalevi Kairemo, President-Elect World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) and Senior Scientific Advisor for INITIO Medical Group. INITIO received the license from the Canadian Nuclear Safety Commission last week and will begin offering patient treatments after March 15. INITIO will be the first private clinic in Canada to offer Lu-177-PSMA treatment, following the approval of the compound by Health Canada in September, 2022. The compound is administered intravenously over about a minute, and it binds to cancer cells and destroys them with ultra short range "beta particles". These particles travel a maximum of 2 mm once emitted by the lutetium nucleus, ensuring they selectively target cancer cells and spare healthy tissue. Any compound which does not bind to cancer tissue is primarily cleared from the body by the kidneys. "Lutetium-177 has demonstrated the ability to meaningfully prolong life in the international VISION trial, involving patients with advanced cancer, many of whom otherwise would have very few therapeutic options. We're excited to offer this treatment in Canada," says Dr. Rob Tarzwell, Medical Director for INITIO Medical Group, and a Clinical Assistant Professor on the Faculty of Medicine at the University of British Columbia. "The approval of this license was made possible by the tireless efforts of our team, who worked closely with regulatory agencies and other stakeholders to ensure that we meet all the necessary requirements and standards," says Dr. Philip Cohen, INITIO Director and Division Head, Nuclear Medicine, Lions Gate Hospital in North Vancouver, adding there are plans to apply for licenses at other facilities across Canada. At present, although Lu-177-PSMA is Health Canada approved and an effective prostate cancer treatment, it is not publicly funded. ABOUT INITIO INITIO is Western Canada's only private PET/CT scan facility. With over 20 years experience, we offer Rapid PET/CT and CT scans and nuclear medicine treatments with no wait list. INITIO has diagnostic scanning for cancer, cognitive impairment, and cardiac sarcoidosis, and now, offers prostate cancer therapy. With this latest addition, INITIO Medical Group reaffirms its commitment to providing the most advanced and effective treatments to its patients. We are proud to be able to offer Lu-177 PSMA therapy and look forward to the positive impact it will have on the lives of those affected by prostate cancer. SOURCE INITIO Medical Group

Radiation Therapy

100 Deals associated with 177Lu-PSMA-I&T

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastasis from malignant tumor of prostate	Phase 3	US	Curium US Holdings LLC	14 Feb 2022
Metastasis from malignant tumor of prostate	Phase 3	FR	Curium US Holdings LLC	14 Feb 2022
Metastasis from malignant tumor of prostate	Phase 3	IT	Curium US Holdings LLC	14 Feb 2022
Metastasis from malignant tumor of prostate	Phase 3	ES	Curium US Holdings LLC	14 Feb 2022
Metastatic castration-resistant prostate cancer	Phase 3	US	Curium US Holdings LLC	14 Feb 2022
Metastatic castration-resistant prostate cancer	Phase 3	FR	Curium US Holdings LLC	14 Feb 2022
Metastatic castration-resistant prostate cancer	Phase 3	IT	Curium US Holdings LLC	14 Feb 2022
Metastatic castration-resistant prostate cancer	Phase 3	ES	Curium US Holdings LLC	14 Feb 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04188587 (Pubmed \| Front Oncol) Manual	Phase 2	Metastatic castration-resistant prostate cancer	40	177 Lu-PSMA-I&T	uctujsxlav(deibeqeuhq) = wilcjzwkpi astpagmunb (jgdpcwnvzq ) View more	Positive	24 Mar 2022
AUA2021	Not Applicable	Prostatic Cancer	7	177Lu-PSMA-I&T	rskdiukwrk(certernjtc) = The only reported adverse event during LuPSMA treatment was fatigue in 1 patient (14%) phxankvokw (mbpxickdbk ) View more	-	01 Sep 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

177Lu-PSMA-I&T

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation